(0.33%) 5 108.50 points
(0.71%) 38 656 points
(0.63%) 17 762 points
(0.14%) $79.06
(0.20%) $2.04
(-0.05%) $2 308.40
(-0.24%) $26.77
(1.13%) $973.50
(-0.13%) $0.931
(-0.54%) $10.93
(-0.22%) $0.796
(0.53%) $91.61
Live Chart Being Loaded With Signals
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies...
Stats | |
---|---|
今日成交量 | 679 660 |
平均成交量 | 372 437 |
市值 | 260.61M |
EPS | $0 ( 2024-04-01 ) |
下一个收益日期 | ( $-0.420 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.12 |
ATR14 | $0.0300 (0.34%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-28 | Nicholson, C. David | Buy | 70 311 | Stock Option (Right to Buy) |
2023-12-28 | Steinhart Richard I | Buy | 70 311 | Stock Option (Right to Buy) |
2023-12-28 | O'loughlin Steve | Buy | 253 123 | Stock Option (Right to Buy) |
2023-12-28 | Shetty Ajit | Buy | 70 311 | Stock Option (Right to Buy) |
2023-12-28 | Seth Sandesh | Buy | 984 367 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 100 transactions |
Buy: 13 159 883 | Sell: 1 707 212 |
音量 相关性
Actinium Pharmaceuticals 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Actinium Pharmaceuticals 相关性 - 货币/商品
Actinium Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $81 000.00 |
毛利润: | $-709 000 (-875.31 %) |
EPS: | $-1.830 |
FY | 2023 |
营收: | $81 000.00 |
毛利润: | $-709 000 (-875.31 %) |
EPS: | $-1.830 |
FY | 2022 |
营收: | $1.03M |
毛利润: | $331 000 (32.14 %) |
EPS: | $-1.320 |
FY | 2021 |
营收: | $1.14M |
毛利润: | $1.14M (100.00 %) |
EPS: | $-2.17 |
Financial Reports:
No articles found.
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。